← Back to all trials
Active Not Recruiting
NCT07835971
A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential Hypertension
Conditions: Hypertension
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 319
Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
Location: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai, China Shanghai Shanghai Municipality
Summary
The purpose of this study is to evaluate the effect of GW906 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of GW906.
Eligibility Criteria
Inclusion Criteria:
* Age ≥ 18 years and ≤ 75 years, of either sex.
* Mean sitting systolic blood pressure (msSBP) ≥ 140 mmHg and \< 180 mmHg at screening.
* Willing to participate in the study and provide written informed consent.
Exclusion Criteria:
* Secondary hypertension.
* orthostatic hypotension.
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5× upper limit of normal (ULN); Total bilirubin \> 1.5 × ULN; International normalized ratio (INR) \> 2.0; Serum potassium \> 5.0 mmol/L or \< 3.5 mmol/L; eGFR≤30 mL/min/1.73m\^2.
* Received an investigational agent within the last 3 months.
* Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus.
* History of any cardiovascular event within 12 months.
* History of intolerance to SC injection(s).
Source: ClinicalTrials.gov (NCT07835971). StuddyBuddy aggregates publicly available trial information.
